Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tyke will you give up banging on about Prv’s. Constant 100-200 million and what was your forecast 50-100p per share. You’re not on Browns payroll are ya! ( seriously let’s be realistic)
Why isn’t the imaging doing more revenue, in with Bayer ( apparently global ) and GM but not seeing any benifits Why. I was under the impression we were waiting for FDA approval so the imaging could be more widely spread through out the USa, there was one submitted in May 22 Fda510k for IBzeroG, does anybody know what’s happening with that application
There’s no significant increase in revs from IB. Given that its software has been embedded in our OEM Kit I have no idea from the financials wtf TB doing for it! Revs are actually down!
This still a jam tomorrow story with chances of high returns that hooks investors in!
Usual caveats
Trek
Just picking up on something Max noticed. 2 PRD applications can mean 2 PRV’s. So in theory possibly $200m+ which would have to be before end of 2026. Now that would be nice.
We can all dream
Thanks
This was from the mid year update last year, “More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.
It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023.”
Where is the step change via easy up sells?
Sales have increased but I would say no where near what we hoped for.
No comment on share price
Stonechecker seems to be non existent now and written off.
Only good news I can see is that we are looking at the global market now not just USA.
I would see very neutral set of results regarding effect on the share price. Hopefully in May we do get some good news.
Oh well, let’s see how TB try to sway shareholders, I expect a few RNSs in the next month just so he can be positive at the AGM.
Thanks
You could argue that my dead dog could do a better job than what he’s doing from his care home.
I also noticed the lack of mention of big pharma around phase 2 talk. That was just a big lie to entice mugs like us to buy the placing being forward sold in my opinion.
Next up is the agm and I’m sure this year we will have to vote to reappoint him as the ceo. He’s not getting my vote. He’ll probably fudge it so ensure he gets reappointed but it would be fun to make him sweat abit if enough of us say no!!
Just from IQAI though ... he has his other companies that he milks
-- BB--
Who puts out an annual financial report at 3.25pm on a Monday?
Probably waited all last week for someone really famous to die to slip it out unnoticed.
I see that TB still takes his £100,000 a year.
Have you not seen the cost of living in Switzerland, bet they don't have Food Banks though.
So no mention of a large pharmaceutical maybe getting involved with phase 2 even though he was plugging that a while back. It states see video link re phase 1 and Eap, were is that
Who puts out an annual financial report at 3.25pm on a Monday. Knob
Goalposts appear to keep changing with PRD application, to be honest a long way to go, they cant be bothered to put results in a RNS, that says a lot, no shareholders letter unless on X later on.
No Fireworks!
Now we have 2 RPD designations on review with news hopefully in May .
Narrowed the odds slightly
Outlook
The new financial year has started off well, and revenue to date is higher than the comparable period in 2023. If this trend continues, we expect to exceed last year's revenue.
Does he mean personally or the company. Again lots of ifs and but. Doesn’t really justify screwing everyone over at the beginning of the year. Funny how they said the proceeds of the placing was going towards the eap now they’re saying their begging charities for it.
23. Prior year adjustment
The accounts have been restated in order to take out a loan to Mike Schmainda that had should have been written off when Imaging Biometrics was acquired.
(last paragraph of report)
-- BB --
I see that TB still takes his £100,000 a year.
-- BB --
Recent years Results have been in April except Covid delay 2020 when it was announced that it would be late .
Gee
I agree TB has to produce something to quell the dissatisfaction. PRD if it is not just a box ticking confirmation then we have been truly misled. Hopefully results tomorrow or Wednesday
Thanks
Agreed PRD is not a given but when you read the first 2 paragraphs of the financial highlights of interim accounts Trevor has boxed himself into a corner with his comments, accounts are not difficult to produce, that’s why I think they are waiting for something positive to go with them and we are due the shareholders letter which will be interesting!
Let’s not get to hopeful on the Prd just because it was in a Rns doesn’t mean we are by anyways guaranteed receiving it. The fact it had to be resubmitted looked quire unprofessional
I’ve now become so wary of anything TB says due to his financial shenanigans.
He will say anything to benifit his finances without it seems any regulatory comeback on him
Morning, personally think results will be neutral, not much different to previous accounts and herein lays Trevor’s problem after what he said in interims back in August 23, Trevor needs something positive to sweeten the news, PRD application being successful will be one of them and they will want to include that with accounts, hopefully it will be this week.
Thanks Kane\Max
So we could well use CPT 3 but are we trying to get upto category 1 with a new application. Hopefully more info when we get the results.
Thanks
Looking into what the cpt codes are and it could explain why we’re valued so low and revenue wise isn’t where many thought it would be by now. From what I’ve read and assuming from the vague information passed down to us we only have a category 3 code and are trying to get a category 1. So hence the drop in price as many would have thought now we have deals with major imaging players the cash would simply roll in. But the spanner in the works which they have explained vaguely although we are still not sure who what and when we will get it, is the code is needed. Once they receive it then we could see a boost in earnings but it’s just more jam tomorrow unfortunately in my opinion.
Different Types of CPT Codes and Their Significance
CPT codes can be broadly categorized into three types: Category I, Category II, and Category III codes.
Category I codes are the most common and widely used. They describe medical procedures and services that are recognized and performed by healthcare professionals regularly. These codes undergo regular updates and revisions to keep up with advancements in medical technology and practices.
Category II codes are optional additional codes used for performance measurement and quality reporting. They are not used for billing purposes but serve as supplementary information to track and evaluate the quality of healthcare services provided.
Category III codes, also known as temporary codes, are used for emerging technologies, procedures, and services that are still undergoing evaluation. These codes are often used for research and data collection purposes and may eventually be promoted to Category I status if they gain widespread acceptance.
Each category of CPT code serves a specific purpose and contributes to the accuracy and efficiency of medical billing and documentation.
Tyke I can see in my crystal ball more ups and downs. But unfortunately more downs until a clear road map of what they’re looking to achieve but don’t hold your hopes we will see one as that will spoil their game of rinse and repeat. We’re almost halfway through 2024 and we’re none the wiser of what if anything has happened to the extra patients enrolled on the trail at the end of last year.
We know more about what we don’t know than what we do know about what we do know. If that makes sense.
Ok for a bit of fun, we all need some a laugh after the last few months. Do you think upon annual results will cause the share price to:
A) Surge upwards
B) Stay roughly the same level
C) Drop even further towards 1p or below.
To start with a bit of positivity I will say A) surge towards 3p. My reason being is the science of IB technology and the drug trial.
Anybody else have thoughts and reasons. What could possibly go wrong?
Thanks, fingers crossed
Have a good weekend everybody. Hopefully good news next week.
Thanks